ArticleBiomedical reports2025
Salivary gland secretory carcinoma with an ETV6::RET fusion: A case report.
Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Secretory carcinoma in the parotid gland: A case report.Molecular and clinical oncology · 2026Article
- Case Report: Discordance between RNA-identifiedFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reports the case of a 25-year-old male patient with salivary gland secretory carcinoma (SC) with the ETV6::RET gene fusion. The patient presented with a left parotid mass and was treated using a superficial parotidectomy. Histological analysis of the tumor demonstrated a combination of cystic, follicular and trabecular patterns in cells, with eosinophilic secretions and a vacuolated cytoplasm. Tumor cells exhibited infiltrative growth into muscle and nerve tissues, accompanied by central stromal hyalinized sclerosis. Immunohistochemically, the tumor cells were positive for S-100, mammaglobin and GATA binding protein 3, and negative for DOG1. The results of the present case demonstrated that the patient possessed SC with the ETV6::RET gene fusion. Following the operation, the patient underwent radiotherapy, leading to a disease-free state at the last follow-up at 1 year and 3 months following surgery. A comprehensive review of 21 SC cases with this gene fusion, including the case reported in the present study, demonstrated that invasive growth, neural and lymphovascular invasion and hyalinized sclerosis were frequently seen on histology, and 11 cases (52%) exhibited advanced-stage disease (>T3 or M1). Thus, salivary gland SC with an ETV6::RET fusion may show infiltrative growth and may be more aggressive compared with salivary gland SC with an ETV6::NTRK3 fusion, which is often associated with an indolent clinical course. Therefore, confirmation of the genetic profile of SC is crucial for the prediction of patient prognosis and administration of an effective therapeutic course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.